Anandamide (in Tocrisolve™ 100)
Cat. No. 1017
Alternative Names: Arachidonylethanolamide, AEA
Chemical Name: N-(2-Hydroxyethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide
Biological ActivityEndogenous cannabinoid and vanilloid receptor agonist, in water-soluble emulsion (for details see TocrisolveTM 100, Cat. No. 1684). Ki values are 89 and 371 nM for CB1 and CB2 receptors respectively; EC50 values are 18, 31 and 27 nM at GPR55, CB1 and CB2 respectively; pKi = 5.68 for rVR1. Also blocks TNF-α-induced NF-kB activation via direct inhibition of IKK. Also available as the pure oil dissolved in ethanol (Anandamine, Cat. No. 1339). Tocrisolve Control (Cat. No. 1684) also available.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Pertwee (1999) Pharmacology of cannabinoid receptor ligands. Curr.Med.Chem. 6 635. PMID: 10469884.
Ross et al (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br.J.Pharmacol. 132 631. PMID: 11159715.
Gardiner et al (2002) Complex regional haemodynamic effects of anandamide in conscious rats. Br.J.Pharmacol. 135 1889. PMID: 11959791.
Kagaya et al (2002) Characterization of the anandamide-induced depolarization of guinea-pig isolated vagus nerve. Br.J.Pharmacol. 137 39. PMID: 12183329.
Sancho et al (2003) Anandamide inhibits nuclear factor-κB activation through a cannabinoid receptor-independent pathway. Mol.Pharmacol. 63 429. PMID: 12527815.
Ryberg et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br.J.Pharmacol. 152 1092. PMID: 17876302.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Anandamide (in Tocrisolve 100), supplier, Endogenous, CB, agonist, water-soluble, emulsion, vanilloid, Cannabinoids, Non-Selective, Receptors, Vanillioid, VR1, TRPV, TRP, Channels, Transient, Receptor, Potential, cb2r, cb1r
Find multiple products by catalog number
New Products in this Area
Potent, high affinity CB1 receptor inverse agonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.